Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 21Recruiting 15Unknown 10Terminated 6Withdrawn 5Active not recruiting 5Not yet recruiting 3Suspended 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Pancreatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Esophageal Squamous Cell Carcinoma 5Triple Negative Breast Neoplasms 3Neoplasms 3Head and Neck Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Thymoma 1Thymic epithelial tumor 1Squamous NSCLC 1Small Cell Lung Carcinoma 1Salivary Gland Malignant Neoplasms 1Pathologic Complete Response 1Pancreatic cancer, adult 1Pancreatic Cancer Resectable 1Melanoma 1Mediastinal Neoplasms 1Locally Advanced Non-Small Cell Lung Cancer 1Gastric Adenocarcinoma 1Fallopian Tube Neoplasms 1Esophageal Squamous Carcinoma 1Carcinoma 1Brain Neoplasms 1Anophthalmia with pulmonary hypoplasia 1Advanced Triple Negative Breast Cancer 1

Interventions

Carboplatin 12pembrolizumab 8Paclitaxel 8Cyclophosphamide 8toripalimab 4sacituzumab govitecan 4olaparib 4Epirubicin 4Drug Therapy 4Doxorubicin 4eribulin 3Capecitabine 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2Radiotherapy 2Injections 2Gemcitabine 2taxane 1poly ICLC 1pirfenidone 1palbociclib 1ivarmacitinib 1inavolisib 1fludarabine 1daratumumab 1camrelizumab 1axatilimab 1anlotinib 1aldesleukin 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Triple Negative Breast Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
150 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06975644 2025-05-22

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

Zhejiang Provincial People's Hospital

Phase NA Not yet recruiting
55 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04301739 2020-03-12

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Shanghai Henlius Biotech

Phase 3 Not yet recruiting
522 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡